HGH Fragment 176-191 and AOD-9604 are close relatives — in fact AOD-9604 is essentially a stabilized, modified version of the same C-terminal growth-hormone fragment. Both are marketed for fat loss on the theory that they reproduce growth hormone's effect on fat without its other actions. The key difference is how far each has been tested, and what that testing found.
At a glance
| HGH Fragment 176-191 | AOD-9604 | |
|---|---|---|
| What it is | The GH fragment (residues 176–191) | A modified, stabilized version of that fragment |
| Modification | Unmodified sequence | An added tyrosine for stability |
| Proposed effect | Lipolysis (fat breakdown) | Lipolysis (fat breakdown) |
| Human trials | None of the fragment itself | Reached human obesity trials |
| Human result | Unknown | Did not beat placebo for weight loss |
| Status | Research chemical, not approved | Not approved as a drug; failed obesity development |
| In sport | Banned (WADA) | Banned (WADA) |
The bottom line
These two are best understood as the same idea at different stages of testing. AOD-9604 is the more developed cousin, and its story is the most informative fact about the whole concept: despite promising animal data, it failed to produce meaningful weight loss beyond placebo in human trials. HGH Fragment 176-191 itself has never been through comparable testing, so its fat-loss claims rest on rodent studies and on a mechanism that its better-studied relative could not translate into results. Neither is an approved or proven fat-loss treatment.
Frequently asked questions
What is the difference between HGH Fragment 176-191 and AOD-9604?
They are closely related. AOD-9604 is a modified, stabilized version of the growth-hormone fragment 176-191, with an added amino acid for stability. AOD-9604 has been studied more, including in human trials, while the plain fragment has not.
Does AOD-9604 or HGH Fragment 176-191 work for fat loss?
Neither is proven. AOD-9604 reached human obesity trials and failed to produce meaningful weight loss compared with placebo. HGH Fragment 176-191 has no convincing human evidence at all. Both are unapproved research chemicals.
Are they the same as HGH?
No. Both are only small fragments of the growth-hormone molecule, selected for fat-metabolism activity. They do not reproduce the full effects of growth hormone and are not a form of HGH therapy.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000. Peer-reviewed study
- Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001. Peer-reviewed study
- Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochem Mol Biol Int. 1993. Peer-reviewed study
- Ng FM, Jiang WJ, Gianello R, et al. Molecular and cellular actions of a structural domain of human growth hormone on lipid metabolism in Zucker fatty rats. J Mol Endocrinol. 2000. Peer-reviewed study
- Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004. Peer-reviewed study
- Cox HD, Smeal SJ, Hughes CM, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015. Peer-reviewed study
- Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015. Peer-reviewed study
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001. Peer-reviewed study